These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

727 related articles for article (PubMed ID: 17603752)

  • 21. Perspectives on lymphangiogenesis and angiogenesis in cancer.
    Holopainen T; Bry M; Alitalo K; Saaristo A
    J Surg Oncol; 2011 May; 103(6):484-8. PubMed ID: 21480240
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phosphodiesterase-5 inhibitor vardenafil enhances angiogenesis through a protein kinase G-dependent hypoxia-inducible factor-1/vascular endothelial growth factor pathway.
    Sahara M; Sata M; Morita T; Nakajima T; Hirata Y; Nagai R
    Arterioscler Thromb Vasc Biol; 2010 Jul; 30(7):1315-24. PubMed ID: 20413734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of geldanamycin on HIF-1alpha mediated angiogenesis and invasion in prostate cancer cells.
    Alqawi O; Moghaddas M; Singh G
    Prostate Cancer Prostatic Dis; 2006; 9(2):126-35. PubMed ID: 16432534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor angiogenesis--a potential target in cancer chemoprevention.
    Bhat TA; Singh RP
    Food Chem Toxicol; 2008 Apr; 46(4):1334-45. PubMed ID: 17919802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Angiogenesis and prostate cancer tumor growth.
    Nicholson B; Theodorescu D
    J Cell Biochem; 2004 Jan; 91(1):125-50. PubMed ID: 14689586
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of angiogenesis in solid tumours: an overview.
    Makrilia N; Lappa T; Xyla V; Nikolaidis I; Syrigos K
    Eur J Intern Med; 2009 Nov; 20(7):663-71. PubMed ID: 19818284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Angiogenesis and anti-angiogenesis in human neoplasms. Recent developments and the therapeutic prospects].
    Vacca A; Ribatti D; Pellegrino A; Dammacco F
    Ann Ital Med Int; 2000; 15(1):7-19. PubMed ID: 10842887
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A mycobacterial iron chelator, desferri-exochelin, induces hypoxia-inducible factors 1 and 2, NIP3, and vascular endothelial growth factor in cancer cell lines.
    Chong TW; Horwitz LD; Moore JW; Sowter HM; Harris AL
    Cancer Res; 2002 Dec; 62(23):6924-7. PubMed ID: 12460908
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma.
    Wu XZ; Xie GR; Chen D
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1178-82. PubMed ID: 17559361
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are tumours angiogenesis-dependent?
    Verheul HM; Voest EE; Schlingemann RO
    J Pathol; 2004 Jan; 202(1):5-13. PubMed ID: 14694516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of cell death in the tumor microenvironment.
    Wouters BG; Koritzinsky M; Chiu RK; Theys J; Buijsen J; Lambin P
    Semin Radiat Oncol; 2003 Jan; 13(1):31-41. PubMed ID: 12520462
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug?
    Cao Y
    Int J Dev Biol; 2011; 55(4-5):557-62. PubMed ID: 21858776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current perspectives on antiangiogenesis strategies in the treatment of malignant gliomas.
    Jansen M; de Witt Hamer PC; Witmer AN; Troost D; van Noorden CJ
    Brain Res Brain Res Rev; 2004 Jul; 45(3):143-63. PubMed ID: 15210301
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Rationale of antiangiogenic therapy].
    Tímár J; Paku S; Tóvári J; Döme B
    Magy Onkol; 2006; 50(2):141-51. PubMed ID: 16888678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Observation of incipient tumor angiogenesis that is independent of hypoxia and hypoxia inducible factor-1 activation.
    Cao Y; Li CY; Moeller BJ; Yu D; Zhao Y; Dreher MR; Shan S; Dewhirst MW
    Cancer Res; 2005 Jul; 65(13):5498-505. PubMed ID: 15994919
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Persistent vascular normalization as an alternative goal of anti-angiogenic cancer therapy.
    Sato Y
    Cancer Sci; 2011 Jul; 102(7):1253-6. PubMed ID: 21401807
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypoxia inducible factor-1 independent pathways in tumor angiogenesis.
    Mizukami Y; Kohgo Y; Chung DC
    Clin Cancer Res; 2007 Oct; 13(19):5670-4. PubMed ID: 17908955
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hypoxia control to normalize pathologic angiogenesis: potential role for endothelial precursor cells and miRNAs regulation.
    Collet G; Skrzypek K; Grillon C; Matejuk A; El Hafni-Rahbi B; Lamerant-Fayel N; Kieda C
    Vascul Pharmacol; 2012; 56(5-6):252-61. PubMed ID: 22446152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Molecular regulation of tumour angiogenesis by nitric oxide.
    Ziche M; Morbidelli L
    Eur Cytokine Netw; 2009 Dec; 20(4):164-70. PubMed ID: 20167555
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adrenomedullin as a therapeutic target in angiogenesis.
    Deville JL; Salas S; Figarella-Branger D; Ouafik L; Daniel L
    Expert Opin Ther Targets; 2010 Oct; 14(10):1059-72. PubMed ID: 20846006
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.